Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.

Abstract: The present invention relates to a composition of the enantiomers of 2-(2-oxopyrrolidin-1-yl)butanamide and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from seizure-related disorders, peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

Abstract: The present invention relates to a composition of the enantiomers of 2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one derivatives and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.

Abstract: Described herein are pharmaceutical compositions for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids. In particular, the compositions include palmitoylethanolamide in non-micronized form, in micronized form (PEA-m), in ultra-micronized form (PEAum) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.

Abstract: The present invention relates to molecules of formula (I) where R1=—SO3H, —PO3H, —PO2(OH)2, —OPO2H2, —NHSO3H, —S(N?H)Me, SH, SR or guanidyl; R?C1-4 alkyl, phenyl or 5 or 6 membered aromatic nitrogen heterocycles; n=1, 2, 3, 4 or 5; X?C=0, C(OH)H, C(OAlk)H, C?S, CH2; Alk=C1-6 alkyl linear, branched or cyclic, optionally hydroxylated or polyhydroxylated; their preparation and use as analgesics and in the treatment of pain induced by chemotherapies.

Abstract: Described herein are pharmaceutical compositions for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids. In particular, the compositions include palmitoylethanolamide in non-micronized form, in micronized form (PEA-m), in ultra-micronized form (PEAum) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.

Abstract: The present invention provides a method of treatment, prevention and/or delay of progression of neuropathic pain by a specific dosing regime of acetam derivatives.

Abstract: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.

Abstract: Dimiracetam is a suitable drug for treating and preventing allodynia, in particular allodynia of the hands and feet, that is or may be induced by antitumoral chemotherapeutic treatment with sorafenib.

Abstract: The present invention relates to molecules of formula (I), deriving from lipoic acid and camosine, their preparation and use as analgesics.

Abstract: The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C1-6alkyl, aryl, CF3; Y is CH2, C?O; X is bond, C?O, SO2, or C?N—CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted as defined in the specification. The compounds are active on chronic pain conditions of different origin; they can be administered alone or with other drugs. Most of these compounds are new. The invention include a process to prepare said compounds, and pharmaceutical compositions suitable for their administration to a patient.

Abstract: The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

Abstract: The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

Abstract: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.

Abstract: The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

Abstract: The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided.

Abstract: The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C1-6alkyl, aryl, CF3; Y is CH2, C?O; X is bond, C?O, SO2, or C?N—CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted as defined in the specification. The compounds are active on chronic pain conditions of different origin; they can be administered alone or with other drugs. Most of these compounds are new. The invention include a process to prepare said compounds, and pharmaceutical compositions suitable for their administration to a patient.

Abstract: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.

Abstract: Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.